{"id":"ezh2","name":"EZH2","symbol":"EZH2","route":"/targets/ezh2/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3527","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000106462","uniprot":"https://www.uniprot.org/uniprotkb/Q15910/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q15910","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2189110","open-targets":"https://platform.opentargets.org/target/ENSG00000106462","civic":"https://civicdb.org/genes/2146/summary","oncokb":"https://www.oncokb.org/gene/EZH2","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EZH2","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=EZH2","depmap":"https://depmap.org/portal/gene/EZH2?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000106462-EZH2","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/2146","omim":"https://www.omim.org/entry/601573"}],"products":[{"id":"mevrometostat","name":"Mevrometostat","status":"phase-3","modality":"Small-molecule EZH2 inhibitor","route":"/drugs/mevrometostat/"},{"id":"tazemetostat","name":"Tazemetostat","status":"withdrawn","modality":"Small-molecule EZH2 inhibitor","route":"/drugs/tazemetostat/"},{"id":"xnw5004","name":"XNW5004","status":"phase-2","modality":"small molecule (structure undisclosed or not yet in PubChem)","route":"/drugs/xnw5004/"}],"trials":[{"id":"nct06776952","name":"A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma","nct":"NCT06776952","phase":"3","status":"recruiting"},{"id":"nct04224493","name":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus ","nct":"NCT04224493","phase":"3","status":"active"},{"id":"nct06629779","name":"A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.","nct":"NCT06629779","phase":"3","status":"recruiting"},{"id":"mevpro-1","name":"MEVPRO-1","nct":"NCT06551324","phase":"3","status":"active"},{"id":"nct07028853","name":"This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking En","nct":"NCT07028853","phase":"3","status":"recruiting"},{"id":"pediatric-match","name":"NCI-COG Pediatric MATCH (APEC1621)","nct":"NCT03155620","phase":"platform","status":"active"},{"id":"nct03213665","name":"Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)","nct":"NCT03213665","phase":"2","status":"completed"},{"id":"nct07545603","name":"Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma","nct":"NCT07545603","phase":"2","status":"recruiting"},{"id":"nct07407283","name":"A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer","nct":"NCT07407283","phase":"1/2","status":"recruiting"},{"id":"nct05372354","name":"A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed ","nct":"NCT05372354","phase":"1/2","status":"recruiting"},{"id":"nct07730515","name":"Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma","nct":"NCT07730515","phase":"1/2","status":"recruiting"},{"id":"nct06702995","name":"Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer","nct":"NCT06702995","phase":"1/2","status":"recruiting"},{"id":"tazemetostat-doxorubicin-es","name":"Tazemetostat with doxorubicin as front-line therapy for advanced epithelioid sarcoma (EZH-301 run-in)","nct":"NCT04204941","phase":"1","status":"withdrawn"}],"pathways":["cancer-stem-cells-plasticity","immune-desert-exclusion","drug-tolerant-persisters","epigenetic-reprogramming","lineage-plasticity-neuroendocrine","micrornas-in-cancer","swi-snf-chromatin","germinal-centre-reaction"],"companies":["evopoint-biosciences","ipsen","oric-pharmaceuticals","pfizer","treeline-biosciences"],"keyPapers":["paper-lehmann-tnbc-subtype-multiomics-nat-commun-2021","paper-wright-lymphgen-genetic-subtypes-dlbcl-cancer-cell-2020","paper-schmitz-genetics-pathogenesis-dlbcl-nejm-2018","paper-ku-rb1-trp53-lineage-plasticity-science-2017"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[{"class":"top1-adc","mechanism":"SLFN11 loss","category":"payload"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}